Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials.

Arch Gynecol Obstet

Department of Obstetrics and Gynecology, Tangdu Hospital, Air Force Medical University, No. 569 Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, People's Republic of China.

Published: June 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To evaluate the efficacy of manifold ovarian stimulation protocols for patients with poor ovarian response.

Methods: PubMed, Embase, Cochrane Library and Web of Science were systematically searched until February 14, 2021. Primary outcomes included clinical pregnancy rate per initiating cycle and low risk of cycle cancellation. Secondary outcomes included number of oocytes retrieved, number of metaphase II (MII) oocytes, number of embryos obtained, number of transferred embryos, endometrial thickness on triggering day and estradiol (E) level on triggering day. The network plot, league table, rank probabilities and forest plot of each outcome measure were drawn. Therapeutic effects were displayed as risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs).

Results: This network meta-analysis included 15 trials on 2173 participants with poor ovarian response. Delayed start GnRH antagonist was the best regimen in terms of clinical pregnancy rate per initiating cycle (74.04% probability of being the optimal), low risk of cycle cancellation (75.30%), number of oocytes retrieved (68.67%), number of metaphase II (MII) oocytes (97.98%) and endometrial thickness on triggering day (81.97%), while for E level on triggering day, microdose GnRH agonist (99.25%) was the most preferred. Regarding number of embryos obtained and number of transferred embryos, no statistical significances were found between different ovarian stimulation protocols.

Conclusion: Delayed start GnRH antagonist and microdose GnRH agonist were the two superior regimens in the treatment of poor ovarian response, providing favorable clinical outcomes. Future investigation is needed to confirm and enrich our findings.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-022-06565-6DOI Listing

Publication Analysis

Top Keywords

poor ovarian
16
triggering day
16
ovarian stimulation
12
stimulation protocols
8
network meta-analysis
8
outcomes included
8
clinical pregnancy
8
pregnancy rate
8
rate initiating
8
initiating cycle
8

Similar Publications

Introduction: Patients with advanced solid tumors may be considered for early phase clinical trials investigating the safety, tolerability, and dosing of experimental therapies. Optimizing participant selection is critical to maximize clinical benefit and meet trial endpoints with fewer participants. One in six participants does not meet routine life expectancy requirements (>3 months), highlighting the need for improved prognostication.

View Article and Find Full Text PDF

Recessive variants in TWNK cause syndromic and non-syndromic post-synaptic auditory neuropathy through MtDNA replication defects.

Hum Genet

September 2025

College of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Chinese PLA Medical School, 28 Fuxing Road, Beijing, 100853, China.

Recessive variants in TWNK cause syndromes arising from mitochondrial DNA (mtDNA) depletion. Hearing loss is the most prevalent manifestation in individuals with these disorders. However, the clinical and pathophysiological features have not been fully elucidated.

View Article and Find Full Text PDF

Introduction: Ovarian cancer has a high mortality rate due to late diagnosis, relapse and chemoresistance. miRNAs play a major role in tumorigenesis as well as chemoresistance. Hence, we undertook a study, to evaluate the differential expression of miRNAs in clinical specimens of ovarian cancer patients that may highlight the effect of chemotherapy and their role in predicting survival outcomes.

View Article and Find Full Text PDF

Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway.

Oncol Res

September 2025

Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, 610041, China.

Objectives: Ovarian cancer, a leading cause of gynecological malignancy-related mortality, is characterized by limited therapeutic options and a poor prognosis. Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors, the precise mechanisms of its antitumor effects remain obscure. This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings.

View Article and Find Full Text PDF

Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer.

Open Med (Wars)

August 2025

Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology and Obstetrics, No. 156, Nankai Sanma Road, Xingnan Street, Nankai District, Tianjin, 300100, China.

Background: The exosomal microRNAs (exomiRNAs) are promising novel biomarkers for clinical detection and prognosis assessment of human cancers. The aim of this study was to identify potential exomiRNAs as biomarkers in ovarian cancer (OC).

Methods: The candidate exomiRNAs were screened by analysis of GSE235525, GSE239685, and GSE216150 datasets and further validated in exosome samples from the serum of 61 patients with OC and OC cell lines by qPCR.

View Article and Find Full Text PDF